All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

  TRANSLATE

The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Johnson & Johnson, and Syndax, and has been supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given.  View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Is AML NPM1mut a candidate for immune checkpoint inhibition?

By Cynthia Umukoro

Share:

Sep 29, 2017


On 21st September 2017, in a Letter to the Editor of  Haematologica, Jochen Greiner et al. from the University of Ulm, Germany, reported results of their study which evaluated whether mutated Nucleophosmin 1 (NPM1mut) Acute Myeloid Leukemia (AML) patients might be candidates  for Programmed Death 1 (PD-1)/Programmed Death-Ligand 1 (PD-L1) directed immune checkpoint inhibition.

Peripheral Blood (PB) samples from NPM1mut (n = 15) and NPM1 Wild-Type (NPM1wt [n = 15]) AML patients at diagnosis were assessed for PD-L1 expression in leukemic cells including the Leukemic Stem Cells (LSCs) compartment using flow cytometry and microarray analysis.

The key results of the study were:

  • Median PD-L1 expression in bulk AML cells was significantly higher in NPM1mut patients compared to NPM1wt patients; 1.4% (range, 0.0–8.5%) vs 0.3% (range, 0.0–1.1%) positive cells, P < 0.0001
  • PD-L1 expression was detected significantly at a higher percentage in the LSCs in NPM1mut AML than in NPM1wt AML; 3.6% (range, 0.0–17.2%) vs 0.3% (range, 0.0–3.0%) positive cells, P < 0.001
  • PD-L1 positive LSCs of NPM1mut AML samples had a significant expression of mutant NPM1

In summary, PD-L1 expression was higher in NPM1mut patients particularly in the LSCs compartment compared to NPM1wt AML cases.

The authors concluded by noting that in NPM1mut AML cases, “the immunogenicity of neoantigens derived from the NPM1 mutation and the higher PD-L1 expression constitute a promising target structures for individualized immunotherapeutic approaches”. 

References

More about...

Your opinion matters

What barriers do you encounter when conducting multiple MRD tests during treatment?